Status:
UNKNOWN
Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors
Lead Sponsor:
Sichuan University
Conditions:
Carcinoma
Melanoma
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
This single center, single arm and prospective study aimed to establish gene mutation database and select the neoantigens in patients with advanced malignant melanoma, bladder cancer and colorectal ca...
Eligibility Criteria
Inclusion
- Age:18-75 years
- Pathologically diagnosed advanced (stage IV) malignant melanoma, bladder cancer or colorectal cancer with measurable lesions;
- Failed in the previous standard therapy;
- ECOG PS (Eastern Cooperative Oncology Group performance status) score 0-2 points;
- The estimated survival period is ≥3 months;
- Rehabilitate from previous therapy;
- Adequate organ functions;
- Patient's written informed consent;
Exclusion
- Tumor emergencies;
- Abnormal coagulation function;
- Contagious diseases, such as HIV, HBV, HCV infection;
- Mental disorders;
- Concomitant tumors;
- Immunological co-morbidities
Key Trial Info
Start Date :
March 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 2 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05235607
Start Date
March 1 2022
End Date
December 2 2023
Last Update
February 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West China Hospital
Chengdu, Sichuan, China, 610000